[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++PL05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Breast cancer,HER2,Immunotherapy,Neoadjuvant treatment,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Guan<\/b>, K. Sun, D. Jain, S. Mathur, H. Mai, P. Niravath, J. Chang; <br\/>Houston Methodist Neal Cancer Center, Houston, TX","CSlideId":"","ControlKey":"3be43bd3-1014-4e88-affc-6d8905536514","ControlNumber":"9564","DisclosureBlock":"&nbsp;<b>J. Guan, <\/b> None..<br><b>K. Sun, <\/b> None..<br><b>D. Jain, <\/b> None..<br><b>S. Mathur, <\/b> None..<br><b>H. Mai, <\/b> None..<br><b>P. Niravath, <\/b> None..<br><b>J. Chang, <\/b> None.","End":"4\/8\/2024 2:40:00 PM","HasWebcast":null,"Highlights":[],"Id":"11405","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT029","PresenterBiography":null,"PresenterDisplayName":"Jian Guan, MD","PresenterKey":"e55cd164-42aa-45fe-aa31-b9f7e4c76c72","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT029. Chemotherapy-free neoadjuvant regimen with durvalumab, trastuzumab and pertuzumab (DTP) in HER2-enriched early breast cancer: A prospective, open-label phase II trial","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  2:30PM","SessionId":"664","SessionOnDemand":"False","SessionTitle":"Advances in Immunotherapy","ShowChatLink":"false","Start":"4\/8\/2024 2:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Chemotherapy-free neoadjuvant regimen with durvalumab, trastuzumab and pertuzumab (DTP) in HER2-enriched early breast cancer: A prospective, open-label phase II trial","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"df022da6-9168-40c0-9ab9-a35bcb7a8f16","ControlNumber":"12151","DisclosureBlock":"","End":"4\/8\/2024 2:45:00 PM","HasWebcast":null,"Highlights":[],"Id":"11850","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"2","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  2:30PM","SessionId":"664","SessionOnDemand":"False","SessionTitle":"Advances in Immunotherapy","ShowChatLink":"false","Start":"4\/8\/2024 2:40:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Microbiome,Immunotherapy,Melanoma\/skin cancers,Cancer immunotherapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"I. C. Glitza Oliva<sup>1<\/sup>, <b>Y. D. Seo<\/b><sup>1<\/sup>, C. N. Spencer<sup>2<\/sup>, J. R. Wortman<sup>3<\/sup>, E. M. Burton<sup>1<\/sup>, F. A. Alayli<sup>2<\/sup>, C. Loo<sup>2<\/sup>, S. Gautam<sup>2<\/sup>, A. V. Damania<sup>1<\/sup>, J. Densmore<sup>2<\/sup>, J. Fairchild<sup>2<\/sup>, C. Cabanski<sup>2<\/sup>, M. C. Wong<sup>1<\/sup>, C. B. Peterson<sup>1<\/sup>, B. Weiner<sup>3<\/sup>, N. Hicks<sup>3<\/sup>, J. Aunins<sup>3<\/sup>, C. McChalicher<sup>3<\/sup>, M. T. Tetzlaff<sup>4<\/sup>, O. Hamid<sup>5<\/sup>, P. A. Ott<sup>6<\/sup>, G. M. Boland<sup>7<\/sup>, R. J. Sullivan<sup>7<\/sup>, K. F. Grossmann<sup>8<\/sup>, N. J. Ajami<sup>1<\/sup>, T. M. LaVallee<sup>9<\/sup>, M. R. Henn<sup>3<\/sup>, H. A. Tawbi<sup>1<\/sup>, J. A. Wargo<sup>1<\/sup>; <br\/><sup>1<\/sup>The University of Texas MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>Parker Institute for Cancer Immunotherapy, San Francisco, CA, <sup>3<\/sup>Seres Therapeutics, Boston, MA, <sup>4<\/sup>University of California San Francisco, San Francisco, CA, <sup>5<\/sup>Cedars Sinai Research Institute, Los Angeles, CA, <sup>6<\/sup>Dana-Farber Cancer Institute, Boston, MA, <sup>7<\/sup>Massachusetts General Hospital Cancer Center, Boston, MA, <sup>8<\/sup>Merck & Co, Rahway, NJ, <sup>9<\/sup>Coherus BioSciences, Redwood City, CA","CSlideId":"","ControlKey":"6791e32b-f27a-4e7e-a398-8b05a34a137c","ControlNumber":"10671","DisclosureBlock":"<b>&nbsp;I. C. Glitza Oliva, <\/b> <br><b>Bristol Myers Squibb<\/b> Other, Consultant. <br><b>Array<\/b> Other, Consultant. <br><b>Novartis<\/b> Other, Consultant. <br><b>Sintetica<\/b> Other, Consultant.<br><b>Y. D. Seo, <\/b> None.&nbsp;<br><b>C. N. Spencer, <\/b> <br><b>Parker Institute for Cancer Immunotherapy<\/b> Employment. <br><b>J. R. Wortman, <\/b> <br><b>Seres Therapeutics<\/b> Employment.<br><b>E. M. Burton, <\/b> None.&nbsp;<br><b>F. A. Alayli, <\/b> <br><b>Parker Institute for Cancer Immunotherapy<\/b> Employment. <br><b>C. Loo, <\/b> <br><b>Parker Institute for Cancer Immunotherapy<\/b> Employment. <br><b>S. Gautam, <\/b> <br><b>Parker Institute for Cancer Immunotherapy<\/b> Employment.<br><b>A. V. Damania, <\/b> None.&nbsp;<br><b>J. Densmore, <\/b> <br><b>Parker Institute for Cancer Immunotherapy<\/b> Employment. <br><b>J. Fairchild, <\/b> <br><b>Parker Institute for Cancer Immunotherapy<\/b> Employment. <br><b>C. Cabanski, <\/b> <br><b>Parker Institute for Cancer Immunotherapy<\/b> Employment.<br><b>M. C. Wong, <\/b> None..<br><b>C. B. Peterson, <\/b> None.&nbsp;<br><b>B. Weiner, <\/b> <br><b>Seres Therapeutics<\/b> Employment. <br><b>N. Hicks, <\/b> <br><b>Seres Therapeutics<\/b> Employment. <br><b>J. Aunins, <\/b> <br><b>Seres Therapeutics<\/b> Employment. <br><b>C. McChalicher, <\/b> <br><b>Seres Therapeutics<\/b> Employment.<br><b>M. T. Tetzlaff, <\/b> None.&nbsp;<br><b>O. Hamid, <\/b> <br><b>Aduro<\/b> Grant\/Contract. <br><b>Akeso<\/b> Grant\/Contract. <br><b>Amgen<\/b> Grant\/Contract. <br><b>Beigene<\/b> Grant\/Contract. <br><b>Bristol Meyers Squibb<\/b> Grant\/Contract. <br><b>Genentech<\/b> Grant\/Contract. <br><b>Immunocore<\/b> Grant\/Contract. <br><b>Idera<\/b> Grant\/Contract. <br><b>Incyte<\/b> Grant\/Contract. <br><b>Janssen<\/b> Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract. <br><b>NextCure<\/b> Grant\/Contract. <br><b>Novartis<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>Sanofi Regeneron<\/b> Grant\/Contract. <br><b>Seagen<\/b> Grant\/Contract. <br><b>Tempus<\/b> Grant\/Contract. <br><b>Zelluna<\/b> Grant\/Contract. <br><b>P. A. Ott, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>Bristol Myers Squibb<\/b> Grant\/Contract. <br><b>Celldex<\/b> Grant\/Contract. <br><b>CytomX<\/b> Grant\/Contract. <br><b>Xencor<\/b> Grant\/Contract. <br><b>Genentech<\/b> Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract. <br><b>Neon Therapeutics<\/b> Grant\/Contract. <br><b>Novartis<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>G. M. Boland, <\/b> <br><b>Olink Proteomics<\/b> Grant\/Contract. <br><b>Teiko Bio<\/b> Grant\/Contract. <br><b>InterVenn Biosciences<\/b> Grant\/Contract. <br><b>Palleon Pharmaceuticals<\/b> Grant\/Contract.<br><b>R. J. Sullivan, <\/b> None.&nbsp;<br><b>K. F. Grossmann, <\/b> <br><b>Merck & Co<\/b> Employment.<br><b>N. J. Ajami, <\/b> None.&nbsp;<br><b>T. M. LaVallee, <\/b> <br><b>Coherus BioSciences<\/b> Employment. <br><b>M. R. Henn, <\/b> <br><b>Seres Therapeutics<\/b> Employment, Stock. <br><b>H. A. Tawbi, <\/b> <br><b>Bristol Myers Squibb<\/b> Grant\/Contract. <br><b>Novartis<\/b> Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract. <br><b>Genentech<\/b> Grant\/Contract. <br><b>GlaxoSmithKline<\/b> Grant\/Contract. <br><b>EMD Serono<\/b> Grant\/Contract. <br><b>Eisai<\/b> Grant\/Contract. <br><b>Dragonfly Therapeutics<\/b> Grant\/Contract. <br><b>RAPT Therapeutics<\/b> Grant\/Contract. <br><b>J. A. Wargo, <\/b> <br><b>Imedex<\/b> Grant\/Contract. <br><b>Dava Oncology<\/b> Grant\/Contract. <br><b>Omniprex<\/b> Grant\/Contract. <br><b>Illumina<\/b> Grant\/Contract. <br><b>Gilead<\/b> Grant\/Contract. <br><b>PeerView<\/b> Grant\/Contract. <br><b>MedImmune<\/b> Grant\/Contract. <br><b>Bristol Myers Squibb<\/b> Grant\/Contract. <br><b>GlaxoSmithKline<\/b> Grant\/Contract. <br><b>Roche\/Genentech<\/b> Grant\/Contract.","End":"4\/8\/2024 2:55:00 PM","HasWebcast":null,"Highlights":[],"Id":"11406","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT030","PresenterBiography":null,"PresenterDisplayName":"Yongwoo Seo","PresenterKey":"a4cd0614-14da-4589-8b9a-cf62aa440b19","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT030. Randomized placebo-controlled, biomarker-stratified phase 1b microbiome modulation trial for metastatic melanoma demonstrates impact of antibiotic pre-conditioning regimen on the microbiome and immunity","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  2:30PM","SessionId":"664","SessionOnDemand":"False","SessionTitle":"Advances in Immunotherapy","ShowChatLink":"false","Start":"4\/8\/2024 2:45:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Randomized placebo-controlled, biomarker-stratified phase 1b microbiome modulation trial for metastatic melanoma demonstrates impact of antibiotic pre-conditioning regimen on the microbiome and immunity","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"b723fa15-6a31-4c3e-b145-2d817212d137","ControlNumber":"12152","DisclosureBlock":"","End":"4\/8\/2024 3:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11851","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"4","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  2:30PM","SessionId":"664","SessionOnDemand":"False","SessionTitle":"Advances in Immunotherapy","ShowChatLink":"false","Start":"4\/8\/2024 2:55:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Pancreatic cancer,Nivolumab,Adenosine,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Z. A. Wainberg<\/b>, J. Link, D. Dawson, L. Rosen, S. Kim, M. Girgis, J. King, J. Hines, S. Sadeghi, O. Olevsky, D. J. Wong, H. Multani, J. Davis, L. Yonemoto, A. Siney, C. Kivork, C.-H. Tseng, T. Donahue; <br\/>UCLA Medical Center, Los Angeles, CA","CSlideId":"","ControlKey":"f6ff122c-e66c-4031-a930-ed8c6cbdb92b","ControlNumber":"10555","DisclosureBlock":"<b>&nbsp;Z. A. Wainberg, <\/b> <br><b>BMS<\/b> Grant\/Contract. <br><b>Amgen<\/b> Other. <br><b>Astra Zeneca<\/b> Other, Consulting. <br><b>Arcus<\/b> Grant\/Contract, Other, Consulting. <br><b>Merck<\/b> Other, Consulting. <br><b>Daiichi<\/b> Other, Consulting. <br><b>Astellas<\/b> Other, Consulting. <br><b>Novartis<\/b> Other, Consulting. <br><b>Pfizer<\/b> Other, DSMB. <br><b>Lilly<\/b> Other, Consulting. <br><b>Seagen<\/b> Other, Consulting.<br><b>J. Link, <\/b> None..<br><b>D. Dawson, <\/b> None..<br><b>L. Rosen, <\/b> None..<br><b>S. Kim, <\/b> None..<br><b>M. Girgis, <\/b> None..<br><b>J. King, <\/b> None..<br><b>J. Hines, <\/b> None..<br><b>S. Sadeghi, <\/b> None..<br><b>O. Olevsky, <\/b> None..<br><b>D. J. Wong, <\/b> None..<br><b>H. Multani, <\/b> None..<br><b>J. Davis, <\/b> None..<br><b>L. Yonemoto, <\/b> None..<br><b>A. Siney, <\/b> None..<br><b>C. Kivork, <\/b> None..<br><b>C. Tseng, <\/b> None..<br><b>T. Donahue, <\/b> None.","End":"4\/8\/2024 3:10:00 PM","HasWebcast":null,"Highlights":[],"Id":"11407","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT031","PresenterBiography":null,"PresenterDisplayName":"Zev Wainberg, MD","PresenterKey":"6aeb6215-8fc3-43e0-b38e-e1ffb5ff1c89","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT031. A pilot clinical trial of neoadjuvant modified FOLFIRINOX plus nivolumab in borderline resectable pancreas cancer","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  2:30PM","SessionId":"664","SessionOnDemand":"False","SessionTitle":"Advances in Immunotherapy","ShowChatLink":"false","Start":"4\/8\/2024 3:00:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A pilot clinical trial of neoadjuvant modified FOLFIRINOX plus nivolumab in borderline resectable pancreas cancer","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"2fb68a90-a7d3-44df-b4a6-b376600e46d4","ControlNumber":"12153","DisclosureBlock":"","End":"4\/8\/2024 3:15:00 PM","HasWebcast":null,"Highlights":[],"Id":"11852","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"6","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  2:30PM","SessionId":"664","SessionOnDemand":"False","SessionTitle":"Advances in Immunotherapy","ShowChatLink":"false","Start":"4\/8\/2024 3:10:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Lung cancer: non-small cell,PD-L1,Epidermal growth factor receptor (EGFR),Pembrolizumab,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. Horiike<\/b><sup>1<\/sup>, H. Wakui<sup>2<\/sup>, S. Sugawara<sup>3<\/sup>, Y. Minegishi<sup>4<\/sup>, S. Tasaka<sup>5<\/sup>, S. Kusumoto<sup>6<\/sup>, T. Sakatani<sup>7<\/sup>, H. Suzuki<sup>8<\/sup>, Y. Hosomi<sup>9<\/sup>, Y. Tambo<sup>10<\/sup>, T. Shimokawa<sup>11<\/sup>, H. Ishida<sup>12<\/sup>, E. Miyauchi<sup>13<\/sup>, K. Naoki<sup>14<\/sup>, T. Fukuhara<sup>15<\/sup>, E. Mura<sup>1<\/sup>, T. Tsurui<sup>16<\/sup>, R. Suzuki<sup>1<\/sup>, N. Iriguchi<sup>1<\/sup>, T. Ishiguro<sup>1<\/sup>, Y. Hirasawa<sup>1<\/sup>, R. Manabe<sup>6<\/sup>, M. Shimokawa<sup>1<\/sup>, R. Ohkuma<sup>1<\/sup>, H. Ariizumi<sup>1<\/sup>, Y. Kubota<sup>1<\/sup>, K. Hamada<sup>8<\/sup>, S. Takenoshita<sup>16<\/sup>, K. Ryu<sup>16<\/sup>, T. Sambe<sup>17<\/sup>, E. Inoue<sup>17<\/sup>, S. Wada<sup>16<\/sup>, K. Yoshimura<sup>16<\/sup>, H. Sagara<sup>6<\/sup>, S. Kobayashi<sup>16<\/sup>, T. Tsunoda<sup>1<\/sup>; <br\/><sup>1<\/sup>Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, <sup>2<\/sup>Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan, <sup>3<\/sup>Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan, <sup>4<\/sup>Department of Respiratory Medicine, Mitsui Memorial Hospital, Tokyo, Japan, <sup>5<\/sup>Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan, <sup>6<\/sup>Division of Respirology and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, <sup>7<\/sup>Division of Respiratory Medicine, NTT Medical Center Tokyo, Tokyo, Japan, <sup>8<\/sup>Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan, <sup>9<\/sup>Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan, <sup>10<\/sup>Department of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Japan, <sup>11<\/sup>Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan, <sup>12<\/sup>Division of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan, <sup>13<\/sup>Department of Respiratory Medicine, Tohoku University Hospital, Sendai, Japan, <sup>14<\/sup>Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Japan, <sup>15<\/sup>Department of Respiratory Medicine, Miyagi Cancer Center, Natori, Japan, <sup>16<\/sup>Showa University Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan, <sup>17<\/sup>Showa University Research Administration Center, Showa University, Tokyo, Japan","CSlideId":"","ControlKey":"32110d39-9efb-40e4-8c2b-badb0dfde153","ControlNumber":"9583","DisclosureBlock":"<b>&nbsp;A. Horiike, <\/b> <br><b>Nihonkayaku<\/b> Grant\/Contract. <br><b>Chugai Pharma<\/b> Grant\/Contract, Other, Local PI, Speaker's Bureau. <br><b>MSD<\/b> Other, Local PI. <br><b>BeiGene<\/b> Other, Local PI. <br><b>Daiichi Sankyo<\/b> Other, Local PI. <br><b>AstraZeneca<\/b> Other, Speaker's Bureau. <br><b>Bristol-Myers Squibb<\/b> Other, Speaker's Bureau. <br><b>Lilly<\/b> Other, Speaker's Bureau. <br><b>Kyowa Hakko Kirin<\/b> Other, Speaker's Bureau. <br><b>Taiho<\/b> Other, Speaker's Bureau. <br><b>EP-SOGO<\/b> Other, Speaker's Bureau. <br><b>Novartis<\/b> Other, Speaker's Bureau. <br><b>Merck<\/b> Other, Speaker's Bureau. <br><b>H. Wakui, <\/b> <br><b>AstraZeneca<\/b> Other, Speaker's Bureau. <br><b>Chugai Pharmaceutical<\/b> Other, Speaker's Bureau. <br><b>Daiichi Sankyo<\/b> Other, Speaker's Bureau. <br><b>Eli Lilly<\/b> Other, Speaker's Bureau. <br><b>Kyowa Kirin<\/b> Other, Speaker's Bureau. <br><b>MSD K.K.<\/b> Other, Speaker's Bureau. <br><b>Nippon Kayaku<\/b> Other, Speaker's Bureau. <br><b>Novartis<\/b> Other, Speaker's Bureau. <br><b>Ono Pharmaceutical<\/b> Other, Speaker's Bureau. <br><b>Pfizer<\/b> Other, Speaker's Bureau. <br><b>Taiho Pharmaceutical<\/b> Other, Speaker's Bureau. <br><b>Takeda Pharmaceutical<\/b> Other, Speaker's Bureau. <br><b>UCB Japan<\/b> Other, Speaker's Bureau. <br><b>S. Sugawara, <\/b> <br><b>AnHeart<\/b> Other, Local PI. <br><b>AstraZeneca<\/b> Other, Local PI, Speaker's Bureau. <br><b>Bristol Myers Squibb<\/b> Other, Local PI, Speaker's Bureau. <br><b>Chugai Pharmaceutical<\/b> Other, Local PI, Speaker's Bureau. <br><b>Dachii-Sankyo<\/b> Other, Local PI. <br><b>Merck Sharp & Dohme<\/b> Other, Local PI, Speaker's Bureau. <br><b>Nippon Boehringer Ingelheim<\/b> Other, Local PI, Speaker's Bureau. <br><b>Ono Pharmaceutical<\/b> Other, Local PI, Speaker's Bureau. <br><b>AbbVie<\/b> Other, Speaker's Bureau. <br><b>Amgen<\/b> Other, Speaker's Bureau. <br><b>Kyowa Kirin<\/b> Other, Speaker's Bureau. <br><b>Lilly<\/b> Other, Speaker's Bureau. <br><b>Merck<\/b> Other, Speaker's Bureau. <br><b>Nippon Kayaku<\/b> Other, Speaker's Bureau. <br><b>Novartis<\/b> Other, Speaker's Bureau. <br><b>Otsuka<\/b> Other, Speaker's Bureau. <br><b>Pfizer<\/b> Other, Speaker's Bureau. <br><b>Taiho Pharmaceutical<\/b> Other, Speaker's Bureau. <br><b>Takeda<\/b> Other, Speaker's Bureau. <br><b>Thermo Fisher Scientific; TOWA Pharmaceutical<\/b> Other, Speaker's Bureau.<br><b>Y. Minegishi, <\/b> None..<br><b>S. Tasaka, <\/b> None.&nbsp;<br><b>S. Kusumoto, <\/b> <br><b>AstraZeneca<\/b> Other, Speaker's Bureau. <br><b>Chugai Pharmaceutical<\/b> Other, Speaker's Bureau. <br><b>Novartis Pharma<\/b> Other, Speaker's Bureau. <br><b>Nippon Kayaku<\/b> Other, Speaker's Bureau. <br><b>Kyorin Pharmaceutical<\/b> Other, Speaker's Bureau. <br><b>Merk sharp and Dohme<\/b> Other, Speaker's Bureau. <br><b>T. Sakatani, <\/b> <br><b>AstraZeneca<\/b> Other, Speaker's Bureau. <br><b>Bristol Myers Squibb<\/b> Other, Speaker's Bureau. <br><b>Chugai Pharmaceutical<\/b> Other, Speaker's Bureau. <br><b>Takeda Pharmaceutical<\/b> Other, Speaker's Bureau. <br><b>H. Suzuki, <\/b> <br><b>AbbVie<\/b> Other, Local PI. <br><b>AstraZeneca<\/b> Other, Local PI, Speaker's Bureau. <br><b>Bristol Myers Squibb<\/b> Other, Local PI, Research funding, Speaker's Bureau. <br><b>Chugai Pharmaceutical<\/b> Other, Local PI, Research funding, Speaker's Bureau. <br><b>Merck Sharp & Dohme<\/b> Other, Local PI, Speaker's Bureau. <br><b>Ono Pharmaceutical<\/b> Other, Local PI, Research funding, Speaker's Bureau. <br><b>Amgen<\/b> Other, Research funding, Speaker's Bureau. <br><b>Eli Lilly<\/b> Other, Speaker's Bureau. <br><b>Guardant Health Japan<\/b> Other, Speaker's Bureau. <br><b>Pfizer<\/b> Other, Speaker's Bureau. <br><b>Takeda Pharmaceutical<\/b> Other, Speaker's Bureau. <br><b>Y. Hosomi, <\/b> <br><b>AstraZeneca<\/b> Other, Speaker's Bureau. <br><b>Eli Lilly Japan<\/b> Other, Speaker's Bureau. <br><b>Taiho Pharmaceutical<\/b> Other, Speaker's Bureau. <br><b>Chugai Pharmaceutical<\/b> Other, Speaker's Bureau. <br><b>Bristol-Myers Squibb<\/b> Other, Speaker's Bureau. <br><b>Kyowa Kirin<\/b> Other, Speaker's Bureau. <br><b>Nippon Kayaku<\/b> Other, Speaker's Bureau. <br><b>Takeda<\/b> Other, Speaker's Bureau. <br><b>Eisai<\/b> Other, Speaker's Bureau. <br><b>Novartis<\/b> Other, Speaker's Bureau. <br><b>Pfizer<\/b> Other, Speaker's Bureau. <br><b>Y. Tambo, <\/b> <br><b>Chugai Pharma<\/b> Other, Speaker's Bureau. <br><b>AstraZeneca<\/b> Other, Speaker's Bureau. <br><b>Taiho<\/b> Other, Speaker's Bureau. <br><b>MSD<\/b> Other, Speaker's Bureau. <br><b>Pfizer<\/b> Other, Speaker's Bureau. <br><b>Kyowa Kirin<\/b> Other, Speaker's Bureau. <br><b>T. Shimokawa, <\/b> <br><b>Bristol Myers Squibb<\/b> Other, Local PI. <br><b>MSD<\/b> Other, Local PI. <br><b>Taiho<\/b> Other, Local PI.<br><b>H. Ishida, <\/b> None.&nbsp;<br><b>E. Miyauchi, <\/b> <br><b>Chugai Pharmaceutical<\/b> Other, Local PI, Research funding, Speaker's Bureau. <br><b>Nippon Kayaku<\/b> Other, Local PI, Speaker's Bureau. <br><b>Taiho Pharmaceutical<\/b> Other, Local PI, Speaker's Bureau. <br><b>Boehringer Ingelheim Japan<\/b> Other, Local PI, Speaker's Bureau. <br><b>Eli Lilly Japan<\/b> Research funding, Speaker's Bureau. <br><b>Amgen<\/b> Other, Speaker's Bureau. <br><b>AstraZeneca<\/b> Other, Speaker's Bureau. <br><b>Bristol Myers Squibb<\/b> Other, Speaker's Bureau. <br><b>Guardant Health Japan<\/b> Other, Speaker's Bureau. <br><b>Ono Pharmaceutical<\/b> Other, Speaker's Bureau. <br><b>Pfizer<\/b> Other, Speaker's Bureau. <br><b>Takeda Pharmaceutical<\/b> Other, Speaker's Bureau. <br><b>Daiichi Sankyo<\/b> Other, Speaker's Bureau. <br><b>Sysmex<\/b> Other, Speaker's Bureau. <br><b>Kyorin<\/b> Other, Speaker's Bureau. <br><b>Eisai<\/b> Other, Speaker's Bureau. <br><b>Merck Biopharma<\/b> Other, Speaker's Bureau. <br><b>Navortis<\/b> Other, Speaker's Bureau. <br><b>K. Naoki, <\/b> <br><b>AstraZeneca<\/b> Other, Speaker's Bureau. <br><b>Bristol Myers Squibb<\/b> Other, Speaker's Bureau. <br><b>Chugai Pharmaceutical<\/b> Other, Speaker's Bureau. <br><b>Nippon Boehringer Ingelheim<\/b> Other, Speaker's Bureau. <br><b>T. Fukuhara, <\/b> <br><b>MSD<\/b> Other, Research funding. <br><b>AstraZeneca<\/b> Other, Research funding. <br><b>Beigene<\/b> Other, Research funding. <br><b>AbbVie<\/b> Other, Research funding.<br><b>E. Mura, <\/b> None..<br><b>T. Tsurui, <\/b> None..<br><b>R. Suzuki, <\/b> None..<br><b>N. Iriguchi, <\/b> None..<br><b>T. Ishiguro, <\/b> None.&nbsp;<br><b>Y. Hirasawa, <\/b> <br><b>MSD<\/b> Other, Speaker's Bureau. <br><b>Bristol-Myers Squibb<\/b> Other, Speaker's Bureau.<br><b>R. Manabe, <\/b> None..<br><b>M. Shimokawa, <\/b> None..<br><b>R. Ohkuma, <\/b> None..<br><b>H. Ariizumi, <\/b> None..<br><b>Y. Kubota, <\/b> None..<br><b>K. Hamada, <\/b> None..<br><b>S. Takenoshita, <\/b> None..<br><b>K. Ryu, <\/b> None..<br><b>T. Sambe, <\/b> None.&nbsp;<br><b>E. Inoue, <\/b> <br><b>Chugai Pharmaceutical<\/b> Independent Contractor. <br><b>Eisai<\/b> Independent Contractor.<br><b>S. Wada, <\/b> None..<br><b>K. Yoshimura, <\/b> None..<br><b>H. Sagara, <\/b> None..<br><b>S. Kobayashi, <\/b> None.&nbsp;<br><b>T. Tsunoda, <\/b> <br><b>Oncotherapy Science Inc<\/b> Patent. <br><b>MSD<\/b> Other, Local PI, Speaker's Bureau. <br><b>Ono Pharmaceutical<\/b> Other, Speaker's Bureau. <br><b>Miyarisan<\/b> Other, Speaker's Bureau. <br><b>Lilly<\/b> Other, Speaker's Bureau. <br><b>Taiho<\/b> Other, Local PI, Speaker's Bureau. <br><b>Daiichi Sankyo<\/b> Other, Local PI. <br><b>Chugai Pharma<\/b> Other, Speaker's Bureau. <br><b>Bristol-Myers Squibb<\/b> Other, Speaker's Bureau. <br><b>AstraZeneca<\/b> Other, Speaker's Bureau.","End":"4\/8\/2024 3:25:00 PM","HasWebcast":null,"Highlights":[],"Id":"11408","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT032","PresenterBiography":null,"PresenterDisplayName":"Atsushi Horiike, MD","PresenterKey":"00f76681-a763-4ef0-b25f-bfb99011cb2f","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT032. Promotive clinical effects of pembrolizumab with necitumumab in patients having advanced non-small cell lung cancer with PD-L1 expression of 50% or higher in a phase II study (K-TAIL-202)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  2:30PM","SessionId":"664","SessionOnDemand":"False","SessionTitle":"Advances in Immunotherapy","ShowChatLink":"false","Start":"4\/8\/2024 3:15:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Promotive clinical effects of pembrolizumab with necitumumab in patients having advanced non-small cell lung cancer with PD-L1 expression of 50% or higher in a phase II study (K-TAIL-202)","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"54bdd58f-aeb3-4e8f-a490-00e3a7a213d6","ControlNumber":"12154","DisclosureBlock":"","End":"4\/8\/2024 3:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11853","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"8","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  2:30PM","SessionId":"664","SessionOnDemand":"False","SessionTitle":"Advances in Immunotherapy","ShowChatLink":"false","Start":"4\/8\/2024 3:25:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Biomarkers,Immune checkpoint blockade,B cells,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. Italiano<\/b><sup>1<\/sup>, S. Cousin<sup>1<\/sup>, C. Bellera<sup>1<\/sup>, J.-P. Guegan<sup>2<\/sup>, J.-P. Metges<sup>3<\/sup>, A. Adenis<sup>4<\/sup>, R. BAHLEDA<sup>5<\/sup>, P. Cassier<sup>6<\/sup>, C. Cantarel<sup>1<\/sup>, M. Kind<sup>1<\/sup>, J. Palussiere<sup>1<\/sup>, L. Vanhersecke<sup>1<\/sup>, A. Bessede<sup>2<\/sup>; <br\/><sup>1<\/sup>Institute Bergonié, Bordeaux, France, <sup>2<\/sup>Explicyte, Bordeaux, France, <sup>3<\/sup>CHU BREST, BREST, France, <sup>4<\/sup>Institut Cancerologie Montpellier, Montpellier, France, <sup>5<\/sup>Gustave Roussy, Villejuif, France, <sup>6<\/sup>Centre Léon Berard, Lyon, France","CSlideId":"","ControlKey":"323feb16-956e-4a87-ac61-90532df3dba7","ControlNumber":"10535","DisclosureBlock":"<b>&nbsp;A. Italiano, <\/b> <br><b>bms<\/b> Grant\/Contract. <br><b>roche<\/b> Grant\/Contract. <br><b>pfizer<\/b> Grant\/Contract. <br><b>bayer<\/b> Grant\/Contract. <br><b>astrazeneca<\/b> Grant\/Contract. <br><b>msd<\/b> Grant\/Contract.<br><b>S. Cousin, <\/b> None..<br><b>C. Bellera, <\/b> None.&nbsp;<br><b>J. Guegan, <\/b> <br><b>Explicyte<\/b> Employment.<br><b>J. Metges, <\/b> None..<br><b>A. Adenis, <\/b> None..<br><b>R. Bahleda, <\/b> None..<br><b>P. Cassier, <\/b> None..<br><b>C. Cantarel, <\/b> None..<br><b>M. Kind, <\/b> None..<br><b>J. Palussiere, <\/b> None..<br><b>L. Vanhersecke, <\/b> None.&nbsp;<br><b>A. Bessede, <\/b> <br><b>Explicyte<\/b> Employment.","End":"4\/8\/2024 3:40:00 PM","HasWebcast":null,"Highlights":[],"Id":"11409","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT033","PresenterBiography":null,"PresenterDisplayName":"Antoine Italiano, MD;PhD","PresenterKey":"b2437d6d-3857-4a75-bae3-60a267fe9e51","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT033. Avelumab combined with regorafenib in solid tumors with tertiary lymphoid structures: A phase 2 REGOMUNE trial cohort","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  2:30PM","SessionId":"664","SessionOnDemand":"False","SessionTitle":"Advances in Immunotherapy","ShowChatLink":"false","Start":"4\/8\/2024 3:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Avelumab combined with regorafenib in solid tumors with tertiary lymphoid structures: A phase 2 REGOMUNE trial cohort","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"1682023e-8872-47ca-bb45-b08a1d0db11d","ControlNumber":"12155","DisclosureBlock":"","End":"4\/8\/2024 3:45:00 PM","HasWebcast":null,"Highlights":[],"Id":"11854","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"10","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  2:30PM","SessionId":"664","SessionOnDemand":"False","SessionTitle":"Advances in Immunotherapy","ShowChatLink":"false","Start":"4\/8\/2024 3:40:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT06-01 Phase III adult clinical trials,,"},{"Key":"Keywords","Value":"Pembrolizumab,PARP inhibitors,Immune checkpoint blockade,Combination therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"M. Hochmair<sup>1<\/sup>, M. Schenker<sup>2<\/sup>, M. Dols<sup>3<\/sup>, T. Kim<sup>4<\/sup>, S.-W. Kim<sup>5<\/sup>, O. Ozyilkan<sup>6<\/sup>, M. Smagina<sup>7<\/sup>, L. Viktoriya<sup>8<\/sup>, T. Kato<sup>9<\/sup>, A. Fedenko<sup>10<\/sup>, F. De Angelis<sup>11<\/sup>, A. Rittmeyer<sup>12<\/sup>, J. Gray<sup>13<\/sup>, A. Greystoke<sup>14<\/sup>, Q. Huang<sup>15<\/sup>, B. Zhao<sup>15<\/sup>, H. Lara-Guerra<sup>15<\/sup>, <b>E. Nadal<\/b><sup>16<\/sup>; <br\/><sup>1<\/sup>Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria, <sup>2<\/sup>Sf Nectarie Oncology Center Craiova and the University of Medicine and Pharmacy of Craiova, Craiova, Romania, <sup>3<\/sup>Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain; Present address: UGC Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain, <sup>4<\/sup>Seoul National University Hospital, Seoul, Korea, Republic of, <sup>5<\/sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of, <sup>6<\/sup>Baskent University Adana Application and Research Center, Adana, Turkey, <sup>7<\/sup>State Budgetary Healthcare Institution, Leningrad Regional Oncology Dispensary, Saint Petersburg, Russian Federation, <sup>8<\/sup>Department of Thoracic Organs, Municipal Nonprofit Enterprise Regional Oncology Center, Kharkiv, Ukraine, <sup>9<\/sup>Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan, <sup>10<\/sup>FSBI National Center of Radiology, Moscow, Russian Federation, <sup>11<\/sup>Integrated Health and Social Services Centres, Montérégie Centre, Greenfield Park, QC, Canada, <sup>12<\/sup>Department of Thoracic Oncology, LKI Lungenfachklinik Immenhausen, Immenhausen, Germany, <sup>13<\/sup>Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL, <sup>14<\/sup>Northern Centre for Cancer Care, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, <sup>15<\/sup>Merck & Co., Inc., Rahway, NJ, <sup>16<\/sup>Institut Català d’Oncologia, L’Hospitalet, Barcelona, Spain","CSlideId":"","ControlKey":"4c84892b-cb8e-4131-839b-3a95b7a83323","ControlNumber":"10458","DisclosureBlock":"<b>&nbsp;M. Hochmair, <\/b> <br><b>AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Pfizer, and Roche<\/b> Other, Honoraria. <br><b>M. Schenker, <\/b> <br><b>MSD, BMS, AstraZeneca, Eli Lilly, Roche, Novartis, Gilead, Mylan, Samsung, Amgen, Daichii Sankyo, Sanofi, Regeneron, BeiGen, Bayer, PharmaMar<\/b> Other, Clinical trial fees to self and institution. <br><b>M. Dols, <\/b> <br><b>Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, Lilly, MSD, Takeda, Pfizer, Kyowa, Sanofi, Janssen<\/b> Other, Consultant or Advisory Role. <br><b>BMS<\/b> Other, Research Funding. <br><b>Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, Lilly, MSD, Takeda, Kyowa, Pierre-fabre, Novocure, Sanofi, Janssen<\/b> Other, Speaking. <br><b>T. Kim, <\/b> <br><b>Amgen, AstraZeneca\/ MedImmune, Boryung, Daiichi-Sankyo, HK inno.N, IMBDx. Inc., Janssen, Novartis, Regeneron, Roche\/Genentech, Samsung Bioepis, Takeda, and Yuhan<\/b> Other, Consulting or advisory roles. <br><b>S. Kim, <\/b> <br><b>Amgen, AstraZeneca, Daiichi Sankyo, Janssen, Takeda, Therapex, Yuhan<\/b> Other, Advisory meetings. <br><b>Amgen, Boeringer Ingelheim, Takeda<\/b> Other, invited as a speaker. <br><b>O. Ozyilkan, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Study funding to institution for the conduct of this study. <br><b>M. Smagina, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Study funding to institution to support the conduct of this study. <br><b>L. Viktoriya, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Funding and research support. <br><b>T. Kato, <\/b> <br><b>AstraZeneca, Chugai, Daiichi-Sankyo, Eli Lilly, Merck KGaA<\/b> Other, Honoraria. <br><b>AbbVie, Amgen, AstraZeneca, BeiGene Blueprint Chugai, Daiichi-Sankyo, Eli Lilly, Haihe, Merck Biopharma, MSD, Novartis, Pfizer, Regeneron Takeda, TurningPoint<\/b> Other, Grants for commissioned\/joint research. <br><b>A. Fedenko, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Study funding to institution for the conduct of this study. <br><b>F. De Angelis, <\/b> <br><b>AstraZeneca, Bristol Myers Squibb, Novartis, Pfizer, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Speaker and advisory board honoraria. <br><b>A. Rittmeyer, <\/b> <br><b>AstraZeneca, AbbVie, BMS, Boehringer Ingelheim, Daichi Sankyo, Eli Lilly, MSD, Novartis, Pfizer, Roche, Genentech<\/b> Other, Grants as an advisor or speaker. <br><b>J. Gray, <\/b> <br><b>AbbVie, Blueprint Medicines, Daiichi Sankyo, Inc (DSI), EMD Serono – Merck KGaA, Gilead Sciences, Inc; IDEOlogy Health; Janssen Scientific Affairs, LLC; Jazz Pharmaceuticals; Loxo Oncology Inc;<\/b> Other, Consultant\/advisor. <br><b>Novartis; OncoCyte Biotechnology Company; Spectrum ODAC; Takeda Pharmaceuticals; Triptych Health Partners<\/b> Other, Consultant\/advisor. <br><b>AstraZeneca, Merck & Co., Inc<\/b> Consultant. <br><b>AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, G1 Therapeutics, Ludwig Institute of Cancer Research, Novartis, Pfizer, Merck & Co., Inc<\/b> Other, Research support. <br><b>A. Greystoke, <\/b> <br><b>AstraZeneca, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Janssen, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; Merck Serono; Novartis; Pfizer; Lilly; Sanofi<\/b> Other, Consultancy and speaker fees. <br><b>Takeda; and Roche<\/b> Other, Consultancy and speaker fees. <br><b>AstraZeneca<\/b> Other, Research funding. <br><b>Q. Huang, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>B. Zhao, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>H. Lara-Guerra, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>E. Nadal, <\/b> <br><b>Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi, Illumina, Janssen, Lilly, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; Pfizer; Qiagen; Roche; Sanofi; Takeda<\/b> Other, Invited speaker. <br><b>Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Lilly, Merck Serono, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; Pfizer<\/b> Other, Advisory board. <br><b>Pierre Fabre; Qiagen; Regeneron; Roche; Takeda; Sanofi<\/b> Other, Advisory board. <br><b>Bristol Myers Squibb, Merck Serono, Roche<\/b> Other, Funding support (Personal and Institutional; no financial interest). <br><b>Apollomics, Pfizer, Roche<\/b> Other, Advisory role (non-financial). <br><b>Spanish Lung Cancer Group (GECP)<\/b> Other, Member of the Steering Committee.","End":"4\/8\/2024 3:55:00 PM","HasWebcast":null,"Highlights":[],"Id":"11410","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT034","PresenterBiography":null,"PresenterDisplayName":"ERNEST NADAL, Unknown","PresenterKey":"b2bb1219-5218-457d-a38c-8c8cc7130f7f","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT034. Results from phase 3 KEYLYNK-008: Pembrolizumab (pembro) with and without maintenance olaparib (ola) after first-line (1L) pembro plus chemotherapy (chemo) for metastatic squamous non-small-cell lung cancer (sqNSCLC)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  2:30PM","SessionId":"664","SessionOnDemand":"False","SessionTitle":"Advances in Immunotherapy","ShowChatLink":"false","Start":"4\/8\/2024 3:45:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Results from phase 3 KEYLYNK-008: Pembrolizumab (pembro) with and without maintenance olaparib (ola) after first-line (1L) pembro plus chemotherapy (chemo) for metastatic squamous non-small-cell lung cancer (sqNSCLC)","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"1f8ce37d-dad6-49de-9e9f-e36ed7d3cd35","ControlNumber":"12156","DisclosureBlock":"","End":"4\/8\/2024 4:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11855","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"12","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  2:30PM","SessionId":"664","SessionOnDemand":"False","SessionTitle":"Advances in Immunotherapy","ShowChatLink":"false","Start":"4\/8\/2024 3:55:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Immunogenic cell death,IAP,Immuno-oncology,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>C. Tiu<\/b><sup>1<\/sup>, W. Yau<sup>2<\/sup>, V. Sanchez-Perez<sup>3<\/sup>, G. Codacci-Pisanelli<sup>4<\/sup>, C. Leung<sup>5<\/sup>, E. S. Andrews<sup>5<\/sup>, B. Basu<sup>5<\/sup>, A. Zachariou<sup>3<\/sup>, T. Prout<sup>3<\/sup>, M. Parmar<sup>3<\/sup>, A. Turner<sup>3<\/sup>, X. Lai<sup>3<\/sup>, Z. Yin<sup>3<\/sup>, K. E. Swales<sup>3<\/sup>, S. Haider<sup>3<\/sup>, T. Lund<sup>6<\/sup>, D. C. Dos Reis<sup>3<\/sup>, T. L. Silveira<sup>7<\/sup>, A. S. Dunlop<sup>8<\/sup>, A.-M. Baker<sup>3<\/sup>, B. Gurel<sup>3<\/sup>, A. Ferreira<sup>3<\/sup>, C. Bertan<sup>3<\/sup>, N. Tunariu<sup>9<\/sup>, E. W. Johnston<sup>10<\/sup>, A. Ring<sup>8<\/sup>, T. Tenev<sup>11<\/sup>, T. Smyth<sup>12<\/sup>, S. Jueliger<sup>12<\/sup>, U. Banerji<sup>6<\/sup>, J. S. de Bono<sup>3<\/sup>, A. Paschalis<sup>13<\/sup>, A. Sharp<sup>1<\/sup>, A. Minchom<sup>9<\/sup>, C. Yap<sup>3<\/sup>, P. Meier<sup>3<\/sup>, J. S. Lopez<sup>14<\/sup>; <br\/><sup>1<\/sup>Institution of Cancer Research, Sutton, United Kingdom, <sup>2<\/sup>The Royal Marsden Hospital (Sutton, Surrey), Sutton, United Kingdom, <sup>3<\/sup>Institute of Cancer Research, Sutton, United Kingdom, <sup>4<\/sup>Cambridge University Hospital, Cambridge, United Kingdom, <sup>5<\/sup>Cambridge University Hospitals, Cambridge, United Kingdom, <sup>6<\/sup>Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, <sup>7<\/sup>Royal Marsden NHS Foundation Trust & Institute of Cancer Research, Sutton, United Kingdom, <sup>8<\/sup>Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, <sup>9<\/sup>Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, United Kingdom, <sup>10<\/sup>Royal Marsden NHS Foundation Trust, London, United Kingdom, <sup>11<\/sup>Institute of Cancer Research, London, United Kingdom, <sup>12<\/sup>Astex Pharmaceuticals, Cambridge, United Kingdom, <sup>13<\/sup>Royal Marsden NHS Foundation Trust and Institution of Cancer Research, Sutton, United Kingdom, <sup>14<\/sup>The Royal Marsden Hospital and Institute of Cancer Research, Sutton, United Kingdom","CSlideId":"","ControlKey":"0ab2039a-2633-4202-8a61-5289f1833f4f","ControlNumber":"9875","DisclosureBlock":"&nbsp;<b>C. Tiu, <\/b> None..<br><b>W. Yau, <\/b> None..<br><b>V. Sanchez-Perez, <\/b> None..<br><b>G. Codacci-Pisanelli, <\/b> None..<br><b>C. Leung, <\/b> None..<br><b>E. S. Andrews, <\/b> None.&nbsp;<br><b>B. Basu, <\/b> <br><b>Varsity Pharma<\/b> Grant\/Contract, Investigator Initiated study grant. <br><b>Genmab<\/b> Other, Consultancy and Data Monitoring Committee. <br><b>A. Zachariou, <\/b> <br><b>Roche<\/b> Travel.<br><b>T. Prout, <\/b> None..<br><b>M. Parmar, <\/b> None..<br><b>A. Turner, <\/b> None..<br><b>X. Lai, <\/b> None..<br><b>Z. Yin, <\/b> None.&nbsp;<br><b>K. E. Swales, <\/b> <br><b>Nuvectis Pharma Inc.<\/b> Grant\/Contract, Other, Employee of ICR where NXP800 was discovere and which is being developed by Nuvectis Pharma Inc.. <br><b>Astra Zeneca<\/b> Grant\/Contract. <br><b>Menarini Richerche<\/b> Grant\/Contract. <br><b>Stemline Therapeutics Inc<\/b> Grant\/Contract.<br><b>S. Haider, <\/b> None..<br><b>T. Lund, <\/b> None..<br><b>D. C. Dos Reis, <\/b> None..<br><b>T. L. Silveira, <\/b> None..<br><b>A. S. Dunlop, <\/b> None..<br><b>A. Baker, <\/b> None..<br><b>B. Gurel, <\/b> None..<br><b>A. Ferreira, <\/b> None..<br><b>C. Bertan, <\/b> None..<br><b>N. Tunariu, <\/b> None..<br><b>E. W. Johnston, <\/b> None.&nbsp;<br><b>A. Ring, <\/b> <br><b>Gilead<\/b> Other, Consultancy and Honoraria for talks. <br><b>AZ Daichi-Sankyo<\/b> Other, Consultancy and Honoraria for talks. <br><b>Novartis<\/b> Other, Consultancy and Honoraria for talks. <br><b>Pfizer<\/b> Other, Consultancy and Honoraria for talks. <br><b>Lilly<\/b> Other, Consultancy and Honoraria for talks. <br><b>Zuellig Pharma<\/b> Other, Consultancy and Honoraria for talks. <br><b>Seagen<\/b> Other, Consultancy and Honoraria for talks. <br><b>MSD<\/b> Other, Consultancy and Honoraria for talks.<br><b>T. Tenev, <\/b> None.&nbsp;<br><b>T. Smyth, <\/b> <br><b>Astex Pharmaceuticals<\/b> Employment. <br><b>S. Jueliger, <\/b> <br><b>Astex Pharmaceuticals<\/b> Employment. <br><b>U. Banerji, <\/b> <br><b>Chugai Pharma<\/b> Other, Research funding. <br><b>PharmEnable<\/b> Other, Advisory Board. <br><b>Ellipses<\/b> Other, Advisory Board. <br><b>Astra Zeneca<\/b> Other, Research funding. <br><b>Onyx<\/b> Other, Research funding. <br><b>BTG<\/b> Other, Research funding. <br><b>Verastem<\/b> Other, Research funding. <br><b>J. S. de Bono, <\/b> <br><b>Amgen; AAA; Bioxcel Therapeutics; Daiichi-Sankyo; Endocyte; Genentech\/Roche; ImCheck Therapeutics; Novartis; Oncternal<\/b> Other, Advisory Board. <br><b>AstraZeneca; Astellas; Bayer; Crescendo; GSK; Janssen; Merck Serono; MSD; Pfizer; Sanofi Anventis;<\/b> Grant\/Contract, Other, Advisory Board. <br><b>Cellcentric; Daiichi; Genetech; Mycrix; Orion; Taiho<\/b> Grant\/Contract. <br><b>Insitute of Cancer Research<\/b> Employment. <br><b>National Institute for Health Reserach (NIHR)<\/b> Other, Senior Investigator. <br><b>Janssen<\/b> Other, Inventor.<br><b>A. Paschalis, <\/b> None.&nbsp;<br><b>A. Sharp, <\/b> <br><b>Sanofi<\/b> Travel. <br><b>Roche Gennentech<\/b> Travel. <br><b>Nurix<\/b> Travel. <br><b>DE Shaw Research<\/b> Other, Advisor. <br><b>CHARM Therapeutics<\/b> Other, Advisor. <br><b>Ellipses Pharma<\/b> Other, Advisor. <br><b>Droia Ventures<\/b> Other, Advisor. <br><b>Astellas<\/b> Other, Speaker honoraria. <br><b>MSD<\/b> Other, Speaker honoraria. <br><b>Institute of Cancer Research<\/b> Employment. <br><b>A. Minchom, <\/b> <br><b>MSD<\/b> Grant\/Contract, Other, Advisory Board. <br><b>Merck Sorono<\/b> Grant\/Contract, Other, Advisory Board\u000d\u000aTeaching Honoraria. <br><b>Astex<\/b> Grant\/Contract. <br><b>Janssen<\/b> Travel, Other, Advisory Board\u000d\u000aTeaching Honoraria. <br><b>Seagen<\/b> Other, Honoraria for teaching. <br><b>GSK<\/b> Other, Teaching honoraria. <br><b>Faron<\/b> Honoraria for data monitoring committee. <br><b>C. Yap, <\/b> <br><b>Novartis<\/b> Grant\/Contract. <br><b>Faron<\/b> Grant\/Contract. <br><b>Astra Zeneca<\/b> Grant\/Contract. <br><b>Celgene Research<\/b> Grant\/Contract, Other, Honoraria.<br><b>P. Meier, <\/b> None.&nbsp;<br><b>J. S. Lopez, <\/b> <br><b>Roche Genentech<\/b> Grant\/Contract. <br><b>GSK<\/b> Other, Scientific Advisory Board. <br><b>Basilea<\/b> Grant\/Contract, Travel, Other, Scientific Advisory Board. <br><b>Astex<\/b> Grant\/Contract. <br><b>MSD<\/b> Grant\/Contract. <br><b>Roche<\/b> Other, Scientific advisory board.","End":"4\/8\/2024 4:10:00 PM","HasWebcast":null,"Highlights":[],"Id":"11411","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"13","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT035","PresenterBiography":null,"PresenterDisplayName":"Crescens Tiu, MBBS","PresenterKey":"014d0fc1-1e98-47bf-aa1f-db1d13a9ed9f","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT035. Proof-of-concept and preliminary efficacy of triple IAP blockade to maximize immunogenic cell death and induce efficient adaptive immune response: First report on the ASTEROID phase 1 trial","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  2:30PM","SessionId":"664","SessionOnDemand":"False","SessionTitle":"Advances in Immunotherapy","ShowChatLink":"false","Start":"4\/8\/2024 4:00:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Proof-of-concept and preliminary efficacy of triple IAP blockade to maximize immunogenic cell death and induce efficient adaptive immune response: First report on the ASTEROID phase 1 trial","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"970fc752-0696-4a5f-bee4-59c24dcd1c12","ControlNumber":"12157","DisclosureBlock":"","End":"4\/8\/2024 4:15:00 PM","HasWebcast":null,"Highlights":[],"Id":"11856","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"14","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  2:30PM","SessionId":"664","SessionOnDemand":"False","SessionTitle":"Advances in Immunotherapy","ShowChatLink":"false","Start":"4\/8\/2024 4:10:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""}]